Skip to Content
MilliporeSigma
All Photos(1)

Documents

A-903

Supelco

Alprazolam solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C17H13ClN4
CAS Number:
28981-97-7
Molecular Weight:
308.76
EC Number:
200-659-6
MDL number:
MFCD00078881
UNSPSC Code:
41116107
PubChem Substance ID:
329771027
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

SNAP-N-SPIKE®, SNAP-N-SHOOT®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

Cc1nnc2CN=C(c3ccccc3)c4cc(Cl)ccc4-n12

InChI

1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3

InChI key

VREFGVBLTWBCJP-UHFFFAOYSA-N

Gene Information

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Alprazolam is a benzodiazepine drug used for the medical treatment of anxiety and panic disorders, including generalized or social anxiety disorder. This certified reference standard is suitable for use in a wide variety of LC/MS or GC/MS testing applications from forensic analysis and clinical toxicology to urine drug testing and pain prescription monitoring. Alprazolam is sold under the trade name Xanax®.

Application


  • Alprazolam Solid Lipid Nanoparticles for Sustained Release: This study explores the development of Compritol-based Alprazolam solid lipid nanoparticles, demonstrating a novel approach for sustained release formulations in benzodiazepine biochemistry. The technique is critical for improving the pharmacokinetics of anxiolytic compounds, ensuring controlled release and enhanced bioavailability (Rao et al., 2022).

  • Extraction of Alprazolam in Biological Samples: Application of dispersive solid-phase extraction using nanographene oxide grafted with α-pyridylamine for alprazolam, which is significant for forensic and clinical toxicology. This method enhances the precision of benzodiazepine detection in complex biological matrices, pivotal for neuropharmacological studies (Parsayi Arvand et al., 2023).

  • Raman Spectroscopy in Drug Abuse Analysis: Utilization of portable Raman spectroscopy for the detection of drugs of abuse, including Alprazolam. This research underscores the importance of Alprazolam research solutions in developing rapid and non-destructive testing methods, contributing to advancements in forensic science (Santos et al., 2022).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Xanax is a registered trademark of Pharmacia & Upjohn Company

related product

Product No.
Description
Pricing

A-902

Alprazolam-d5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-904

alpha-Hydroxyalprazolam-d5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-907

alpha-Hydroxyalprazolam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-908

alpha-Hydroxyalprazolam-d5 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-910

Alprazolam-d5 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-033

Benzodiazepine Multi-component Mixture-8 solution, 250 μg/mL each component in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

IMF-020S

iMethod Test Kit for Benzodiazepines with Synthetic Urine, kit of 23 × 1.0 mL ampules, certified reference material, Cerilliant®

H-142

4-Hydroxyalprazolam solution, 1 mg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

H-143

4-Hydroxyalprazolam-D5 solution, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

F-095

Flualprazolam solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

F-096

Flualprazolam-D4 solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

B-108

Bromazolam solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Storage Class

3 - Flammable liquids

wgk_germany

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 8

1 of 8

Lorazepam solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-901

Lorazepam solution

Amobarbital solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

A-020

Amobarbital solution

alpha-Hydroxyalprazolam solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

A-907

alpha-Hydroxyalprazolam solution

N-(4-amino-3-methoxyphenyl)methanesulfonamide AldrichCPR

PH010250

N-(4-amino-3-methoxyphenyl)methanesulfonamide

Nitrazepam solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

N-906

Nitrazepam solution

Diazepam solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

D-907

Diazepam solution

Chlordiazepoxide solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

C-022

Chlordiazepoxide solution

alpha-Hydroxyalprazolam-d5 solution 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

A-904

alpha-Hydroxyalprazolam-d5 solution

Dean T Acheson et al.
Human psychopharmacology, 27(4), 419-427 (2012-07-12)
Heightened anticipation of future events has been characterized as a feature of certain anxiety disorders. In functional magnetic resonance imaging studies, anticipation of fearful/threatening images has been shown to robustly activate the insular cortex and amygdala in healthy subjects, in
J M Jonas et al.
The Journal of clinical psychiatry, 54 Suppl, 25-45 (1993-10-01)
A review of the worldwide published literature was conducted to assess the efficacy and safety of alprazolam for the treatment of anxiety disorders, panic disorder, and depression in comparison with those of other active drugs (including other benzodiazepines and antidepressant
E M Sellers et al.
The Journal of clinical psychiatry, 54 Suppl, 64-75 (1993-10-01)
The incidence of nonmedical use of alprazolam is very low relative to its widespread legitimate medical use; in fact, given the millions of patients who have received this medication, the incidence is remarkably small. In particular, among patients with anxiety
J O Cole et al.
The Journal of clinical psychiatry, 54 Suppl, 49-61 (1993-10-01)
A review of the published case reports of adverse behavioral episodes or unexpected psychopathology in patients taking benzodiazepines was undertaken in an attempt to determine if these adverse or unexpected events are more likely to occur with alprazolam when compared
Steven Moylan et al.
The Australian and New Zealand journal of psychiatry, 46(3), 212-224 (2012-03-07)
To investigate the potential impact of increasing prescription rates of alprazolam for the treatment of panic disorder (PD) in Australia through a review of efficacy, tolerability and adverse outcome literature. Data were sourced by a literature search using MEDLINE, Embase
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service